Objective: Two of the most commonly prescribed new antiepileptic drugs as add-on therapy for patients with chronic refractory epilepsies are topiramate and levetiracetam. In regulatory trials, both drugs were characterized as very promising new antiepileptic drugs. However, results from these highly controlled short-term clinical trials cannot simply be extrapolated to everyday clinical practice, also because headto-head comparisons are lacking. Therefore, results from long-term open label observational studies that compare two or more new AEDs are crucial to determine the long-term performance of competing new antiepileptic drugs in clinical practice. Method: We analyzed all patients referred to a tertiary epilepsy centre who had been treated with topiramate from the introduction of the drug in spring 1993 up to a final assessment point mid-2002 and all patients who had been treated with LEV in the same centre from the introduction of the drug in early 2001 up to a final assessment point end-2003 using a medical information system. Results: Three hundred and one patients were included for levetiracetam and 429 patients for TPM. Retention rate after 1 year was 65.6% for LEV-treated patients and 51.7% for TPM-treated patients ( p = 0.0015). Similarly, retention rates for LEV were higher at the 24-month mark: 45.8% of LEV-treated patients and 38.3% of TPM-treated patients were still continuing treatment ( p = 0.0046). Adverse events led to drug discontinuation in 21.9% of TPM-treated patients compared to 6.0% of LEV-treated patients ( p < 0.001). The number of patients discontinuing treatment because of lack of efficacy was similar for both groups. Seizure freedom rates varied between 11.6 and 20.0% for TPM and between 11.1 and 14.3% for LEV per 6-months interval. Several
Introduction
The introduction of several new antiepileptic drugs (AEDs) in the past decades may be a welcome development for patients with refractory epilepsy. 1 Two of the most commonly prescribed ''new generation'' AEDs in the Netherlands are topiramate (TPM) and levetiracetam (LEV). Both drugs were found to be an effective and safe therapeutic option as adjunctive therapy for partial seizures in adults during the regulatory well-controlled trials. [2] [3] [4] [5] [6] [7] [8] [9] Even though only TPM has also FDA approval for primary generalized seizures, evidence is growing that LEV may be a useful broad-spectrum AED as well. 10 The most frequently reported side effects associated with the use of LEV in pooled analyses of the regulatory trials were somnolence, asthenia, headache and dizziness.
11 TPM-associated adverse events were predominantly central nervous system-related symptoms, including somnolence, dizziness and psychomotor slowing. 12 However, these clinical trials were designed for registration purposes. Regulatory studies only show antiepileptic activity compared with placebo. It is impossible to transfer findings derived from such trials to everyday clinical practice 13 and make comparisons between AEDs. In order to overcome the shortcomings of those trials and to provide data that can help clinicians in making treatment decisions, other methods must be used to compare competing new AEDs. Ideally, evidence-based treatment guidelines will use information from large multicenter randomized controlled trials that compare AEDs. These studies are, however, rarely performed. Therefore, results from meta-analysis and longterm open label observational studies may give clinicians a possibility to compare the newer AEDs despite the limitations of indirect comparisons.
One way to compare the long-term performance of AEDs in clinical practice is to evaluate retention rates. Retention rate is considered to be a composite of drug efficacy and drug safety and expresses the willingness of patients to continue drug treatment. It is therefore clinically the most relevant parameter of an antiepileptic drug.
14 Although TPM and LEV were characterized as very promising AEDs in regulatory trials, a long-term study that retrospectively compared the retention rates of five new AEDs has shown retention rates of 44% for TPM and 54% for LEV 15 after 2 years of follow-up. This implies that about half of the patients will discontinue treatment within a period of 2 years. Prospective data from long-term open-label studies showed seizure freedom rates of about 10% for at least 6 months in patients on TPM and LEV. However, withdrawal rates due to adverse events were higher for TPM. 16, 17 Presently, only few data are available to show how TPM compares to LEV in the long-term in a single tertiary epilepsy centre. We therefore performed a systematic audit of TPM and LEV in the 'real life' setting of our centre with the aim to compare the long-term effects of both drugs in a broad population, specifically retention time, efficacy and tolerability in clinical practice.
Method
The study was approved by the Medical Ethics Committee. All patients who had been treated with TPM in the Epilepsy Centre Kempenhaeghe from the introduction of the drug in spring 1993 up to a final assessment point mid-2002 and all patients who had been treated with LEV in the same centre from the introduction of the drug in early 2001 up to a final assessment point end-2003 were identified by means of our automated medical information system (MIS) and subsequently analyzed. Patients whom had TPM or LEV prescribed initially elsewhere were not included. The follow-up period for both drugs was 24 months. A standardized data form was developed. The data were obtained from our MIS and individual patient medical records. Variables that were included in the database were patient characteristics (age, sex, weight, age at onset of seizures, duration of epilepsy at the introduction of drug treatment, mental retardation [defined as IQ < 70], CT/MRI abnormalities), length of treatment, efficacy, reported side effects and reasons for discontinuation. Epilepsy and seizures were classified using the International League Against Epilepsy (ILAE) classification. Treatment was evaluated every 6 months for both drugs. Efficacy was measured using a 5-point scale: seizure remission, any reduction in seizure frequency, no efficacy, any important AED specific adverse events leading to drug discontinuation were identified, including neurocognitive side effects from TPM and mood disorders from LEV. Conclusion: The retention rate for LEV is significantly higher than for TPM. LEV had a more favourable side effect profile than TPM with comparable efficacy. Patients on TPM discontinued treatment mainly because of neurocognitive side effects. In the treatment with LEV, the effects on mood must not be underestimated. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. increase in seizure frequency or not classified. Reason for discontinuation of LEV and TPM was entered into the database using a 4-point scale: no efficacy, adverse events, both or other. Mood disorders due to use of AEDs were classified into activating and sedating effects, with the former leading to aggression, hyperirritability and agitation, and the latter leading to apathy and depression. 18, 19 Data forms were entered into a computerized database for analysis. Statistical analysis was performed using SPSS 15.0 for Windows. Retention rates were calculated by using Kaplan-Meier survival analysis, 20 and comparisons between the retention curves of TPM and LEV were analyzed using log-rank tests. Comparison between both drugs in terms of seizure remission and reason for discontinuation was analyzed using Pearson X 2 .
Results
Three hundred and four patients were identified using LEV and 470 patients using TPM. For LEV, three patients were excluded; one patient was already exposed to LEV on referral to our centre and of two patients data were lacking. For TPM, 41 patients were excluded; 37 patients were already exposed to TPM on referral to our centre and of 4 patients data were lacking. Table 1 lists the main characteristics of the patients. The mean age was 32.5 AE 16.8 years for LEV and 34.9 AE 8.6 years for TPM. There was an equal distribution with respect to gender. Age at onset of seizures was in the 11th and 9th year, respectively, with a duration of active epilepsy (= years with seizures) of more than 20 years. Localization-related epilepsy was by far the most prevalent type of epilepsy and, consequently, partial onset seizures the most frequently recorded type of seizure. Children and mentally handicapped patients were substantially and equally represented in both study groups. The number of patients with abnormalities on CTand MRI were similar for the two groups. No difference could be identified in the number of concomitant AEDs and the most frequently used AEDs. Thus, both populations were Long-term effects of levetiracetam and topiramate in clinical practice 21 Fig. 1 . Retention rate after 1 year was 65.6% for LEV-treated patients and 51.7% for TPM-treated patients ( p = 0.0015). Similarly, retention rates for LEV were significantly higher at the 24-month mark: 45.8% of LEV-treated patients and 38.3% of TPMtreated patients were still continuing treatment ( p = 0.0046). However, at 6 months follow-up, there was no significant difference between the two profiles ( p = 0.1088). For both drugs, it is shown that the largest percentage of discontinuations occurred in the first period of treatment with a rapid drop of retention rates until about 400 days, after which a plateau seems to be reached.
The main reasons for drug discontinuation are shown in Fig. 2 . Adverse events led to drug discontinuation in 21.9% of TPM-treated patients compared to 6.0% of LEV-treated patients ( p < 0.001). The number of patients discontinuing treatment because of lack of efficacy or the combination of lack of efficacy and adverse events was similar for both groups.
For LEV, adverse events were the most important reason for drug discontinuation during the first 3 months. Thereafter, lack of efficacy played the most important role in drug discontinuation. For TPM, however, tolerability issues lasted much longer and were the main reason for drug discontinuation in the first 18 months.
Seizure freedom rates per 6-month interval are illustrated in Fig. 3A . Seizure freedom rates varied between 11.6 and 20.0% for TPM and between 11.1 and 14.3% for LEV. No statistically significant differences between TPM and LEV could be identified at 6 months ( p = 0.468), 12 months ( p = 0.653) and 18 months ( p = 0.244). Fig. 3B shows the number of patients completely seizure-free for at least 1 year. Seizure remission rates for the intervals T0-T12 and T0-T18 were higher for LEV, although not statistically significant ( p = 0.618 and 0.416, respectively). For the interval T6-T18, remission rates were similar for both drugs ( p = 0.929). Table 2 shows the most frequently reported adverse events per assessment point. The most prevalent adverse events for LEV were activating mood disorders and tiredness. Some patients experienced a positive effect on their behaviour due to LEV use. For TPM, mental slowing and dysphasia were the most important side effects at each assessment point, except for the 24-month assessment point.
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H.P.R. Bootsma et al. The most frequently reported side effects in patients who discontinued treatment are listed in Table 3 . For LEV, more than a quarter of patients (26.9%) reported mood disorders at the time of discontinuation, with an equal distribution of activating and sedating mood disorders. Tiredness and sleepiness were also important side effects at time of discontinuation (13.8 and 8.5%, respectively). In patients on TPM, mood disorders were also frequently reported (18.9%), although sedating mood disorders played a less important role. Side effects other than mood disorders that most often led to discontinuation of TPM treatment were mental slowing (27.8%) and dysphasia (15.0%). Other side effects that were frequently reported were gastrointestinal complaints, paresthesia, appetite loss, skin complaints, weight loss, headache and dizziness. Table 4 shows seizure reduction in patients who discontinued treatment. One patient (0.8%) was seizure-free when discontinuing LEV compared to four patients (1.8%) who were seizure-free on TPM. In spite of the anticonvulsive effect of drug treatment, twice as many patients discontinued TPM. More patients on LEV experienced no efficacy or even a higher seizure frequency compared to patients on TPM.
Discussion
While many studies have been done on each individual new AED as add-on therapy, few compare these new AEDs with each other. Especially large multicenter randomized controlled trials that compare two or more AEDs are rare but crucial in clinical decision-making. Pharmaceutical companies have serious reservations funding these trials, unless there was confidence that the sponsor's drug was Long-term effects of levetiracetam and topiramate in clinical practice 23 very likely to prove superior to the comparator. In the absence of such comparative clinical trials, indirect comparisons have been made using metaanalyses of controlled trials and reviews of longterm open-label studies to adequately evaluate the benefits and risks of treatment of epilepsy. The relevance of findings derived from such studies to everyday clinical practice is limited by several factors, especially by the indirect character of the comparisons due to differences between studies in study design, study population and placeboeffect. 21, 22 However, both methods have gone some way to compare new AEDs and provide some evidence of the relative efficacy and tolerability of competing new AEDs. Moreover, observational studies are known to be useful adjuncts to controlled trials to see whether the demonstrated efficacy and safety translates into effective and safe treatment in routine clinical practice. 23 Our study directly compared the use of TPM with LEV, presently two of the most commonly prescribed new AEDs in chronic epilepsy. The study population consisted of patients with chronic refractory epilepsy referred to a single tertiary epilepsy centre. The added value of this study is due to the head-tohead comparison made between TPM and LEV in a single epilepsy centre, the large number of patients included (n = 301 for LEV; n = 429 for TPM), the long period of evaluation (24 months) and the low risk of selection bias by the inclusion of all patients who were treated with LEV or TPM in a certain period. This is illustrated by the characteristics of our study population, specifically by a wide age range and a large number of children and mentally retarded. The patients on LEV did not differ on any of the clinical or demographical variables when compared to the patients on TPM, which allows us to compare TPM to LEV and to assume that differences in outcome are drug-related.
For clinical decision-making, retention rate is a good indicator of the long-term performance of a new AED. 24 It measures all possible reasons for drug discontinuation, including ineffectiveness and intolerability. In addition, it expresses the consent of an individual patient to continue drug treatment, sometimes even with side effects. Therefore, the main purpose of our study was to determine longterm retention rates for TPM and LEV. Retention rates were 65.6 and 45.8% for LEV and 51.7 and 38.3% for TPM after 1 and 2 years, respectively. Other studies showed similar 1-year retention rates ranging from 60 to 75% for LEV and 40 to 60% for TPM. 21 The statistically significant difference in 1-and 2-year retention rates is probably the consequence of a more unfavourable safety profile of TPM. At 6 months follow-up, no significant difference was seen between both drugs. This implies that it is hard to show differences in discontinuation rates between TPM and LEV in short-term trials, even when a large number of patients are investigated.
Several findings with regard to retention rates were noteworthy in our study. Retention rates could have been influenced by the sequence in which both drugs were marketed. Patients on TPM could have been withdrawn from treatment because of the availability of the new AED LEV. On the other hand, LEV could have been tested in a more refractory population, since LEV was introduced onto the market years after TPM.
Interestingly, the difference between continuation rates for both drugs became smaller after 1-year follow-up. We do not know whether there will still be a significant difference after many years. This is an important issue, since patients with refractory epilepsy often need lifetime treatment. One study that compared the long-term retention rates of new AEDs in a residential community of adults with chronic epilepsy showed a similar difference in 2-year retention rates between TPM and LEV compared with our study. However, this difference almost disappeared after 5 years. 25 Elsewhere, our study group showed 1-, 2-, 3-and 4-year retention rates for TPM to be 53, 45, 38 and 30%, respectively. 26 These data suggest that surviving the early stage of TPM introduction is a good indicator of long-term retention, with most withdrawals occurring in the first year. With LEV use, we have shown a similar pattern with most patients also discontinuing treatment in the first year, after which the number of withdrawals more or less remained steady at a lower rate.
Drugs that were mostly encountered as concomitant therapy were carbamazepine, clobazam, phenytoin, lamotrigine, oxcarbazepine and valproic acid. At baseline, no differences in the most frequently used concomitant AEDs between TPM and LEV could be identified. Since both drugs were prescribed as adjunctive treatment to an existing regime, we assume that similar baseline concomitant AEDs characteristics prolonged during followup. However, if not so, differences in concomitant AEDs between TPM and LEV could have influenced the efficacy and safety profile of each individual drug.
In our study, percentages of patients discontinuing drug treatment because of lack of efficacy were similar for both study groups, suggesting TPM and LEV to be equally effective. A meta-analysis of wellcontrolled trials showed comparable efficacy between both drugs using a responder rate of !50% reduction in seizure frequency. 22 Zaccara et al. who reviewed long-term open-label studies used seizure-free outcomes as a measure of efficacy. LEV turned out to be the most effective agent, followed by TPM. However, analysis limited to prospective studies showed that TPM had the highest percentage of seizure-free patients. 21 Main objective in the treatment of epilepsy is control of seizures. The achievement of seizure freedom is an essential outcome measure, because it has the greatest impact on quality of life 27 and it is the efficacy measure that is subject to the least subjectivity. Responder rates, defined as a percentage reduction in seizure frequency, do not take into account the duration and severity of seizures. In addition, data reflecting the number of seizures are often unreliable, especially in retrospective studies. Therefore, our study only presented data regarding seizure freedom rates, although seizure remission is not a realistic goal for every patient with refractory epilepsy.
Comparable percentages of patients on TPM and LEV achieved seizure freedom for 6 months in our study. Between 11.6 and 20.0% of patients on TPM were seizure-free compared to 11.1-14.3% of patients on LEV. These figures compare well to those presented in literature, although seizure freedom rates vary a lot among different studies. Four to twenty-three percent of patients were reported to be free of seizures on TPM compared to 9.8-26.0% of patients on LEV, dependent on study design and study population. 21 The proportion of patients with complete seizure control for longer periods of time provides even more clinically meaningful data for predicting the long-term efficacy of an AED. 23 Therefore, we have also investigated long-term seizure remission. From baseline, more patients on LEV achieved seizure remission for at least 1 year, although this difference was not statistically significant. Possibly, this difference is due to a rapid onset of action of LEV. 28 However, if the titration period is not taken into account (i.e. in the interval T6-T18), prolonged seizure remission was achieved in more than 12% of patients in both the TPM and LEV study group, which is a good result in this highly refractory population.
As a marker of tolerability, we used the percentage of patients withdrawing drug treatment because of adverse events. Our study shows that significantly more patients discontinued TPM treatment because of adverse events than patients on LEV. This is also illustrated by the time period in which adverse events were the main reason for drug discontinuation; only in the first 3 months side effects played a more important role than lack of efficacy with LEV use compared to the first 18 months in patients on TPM. Titration rates are unlikely to be responsible for the high incidence of adverse events in patients on TPM. 26 Thus, TPM was by far the least well-tolerated drug. This finding is supported by other studies reporting that TPM has a higher rate of adverse events leading to withdrawal than LEV 16, 21, 22 and by our data showing that twice as many patients on TPM discontinued treatment despite the beneficial effects on seizure frequency compared to LEV. In these patients, the adverse events can therefore be considered very serious.
Side effect profiles of TPM and LEV are different; neurocognitive complaints are very common in TPM treatment and frequently led to drug withdrawal, while the impact of LEV on cognitive function is only very mild. One study showed that the neurocognitive effects of TPM occurred already at an early stage, while the remaining patients do not have such problems. 29 However, in our study, the percentage of patients with neurocognitive side effects due to TPM use remained high. Mood disorders were reported in both drugs, but is was the most common reason for discontinuation in patients on LEV. This contributes to clinical reports that behavioural adverse events are more common in LEV than in TPM 30 and that patients taking LEV experience more behavioural symptoms than reported in RCTs. 31 In our study, mood disorders in patients on LEV emerged from the beginning. It is therefore not clear why RCTs only reported somnolence, asthenia, headache and dizziness as major side effects. An explanation could be that patients with learning disabilities are more prone to behavioural side effects. 31 This population is often excluded in well-controlled randomized clinical trials and some large scale open-label multicenter trials with reports of behavioural adverse events only occurring at a low rate. 32, 33 In conclusion, the retention rate for LEV is significantly higher than for TPM. LEV had a more favourable side effect profile than TPM with comparable efficacy. Patients on TPM discontinued treatment mainly because of neurocognitive side effects. In the treatment with LEV, the effects on mood must not be underestimated.
